Novartis/Ophthotech eye drug fails in nAMD trials
Novartis’ plans to develop a combination of Lucentis with pegpleranib to treat patients with neovascular age-related macular degeneration (nAMD) have suffered a setback after it failed to induce better outcomes than Lucentis alone in late-stage studies.
Read More
